Zell-Baran, Lauren M.
Humphries, Stephen M.
Moore, Camille M.
Lynch, David A.
Charbonnier, Jean-Paul
Oh, Andrea S.
Rose, Cecile S.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U01 HL089897 and U01 HL089856)
COPD Foundation (Industry Advisory Committee comprised of AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sunovion)
Office of the Assistant Secretary of Defense for Health Affairs (W81XWH-16-2-0018)
National Jewish Health (Sergeant Sullivan Fund)
Article History
Received: 10 December 2021
Accepted: 21 April 2022
First Online: 27 April 2022
Declarations
:
: This work was performed in accordance with the Declaration of Helsinki and was approved by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board (HS-3022-528 and HS-2689-528). All participants provided informed consent.
: Not applicable.
: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
: The authors declare that they have no competing interests.